Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Assets (2019 - 2025)

Historic Assets for Strata Critical Medical (SRTA) over the last 7 years, with Q3 2025 value amounting to $335.1 million.

  • Strata Critical Medical's Assets rose 1842.51% to $335.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.1 million, marking a year-over-year increase of 1842.51%. This contributed to the annual value of $256.7 million for FY2024, which is 1297.32% down from last year.
  • According to the latest figures from Q3 2025, Strata Critical Medical's Assets is $335.1 million, which was up 1842.51% from $257.9 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Assets registered a high of $346.1 million during Q2 2021, and its lowest value of $250.6 million during Q1 2025.
  • Over the past 5 years, Strata Critical Medical's median Assets value was $320.2 million (recorded in 2023), while the average stood at $305.7 million.
  • In the last 5 years, Strata Critical Medical's Assets surged by 183843.64% in 2021 and then tumbled by 1297.32% in 2024.
  • Strata Critical Medical's Assets (Quarter) stood at $335.9 million in 2021, then dropped by 3.23% to $325.0 million in 2022, then fell by 9.26% to $294.9 million in 2023, then dropped by 12.97% to $256.7 million in 2024, then skyrocketed by 30.55% to $335.1 million in 2025.
  • Its Assets was $335.1 million in Q3 2025, compared to $257.9 million in Q2 2025 and $250.6 million in Q1 2025.